Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312543 | 0.90 | SLC6A1 (0.33) | DPP4SLC6A2SLC6A4SLC6A3CPN1 | |
| SCHEMBL7383261 | 0.90 | SLC6A1 (0.33) | DPP4SLC6A2SLC6A4SLC6A3CPN1 | |
| SCHEMBL7390438 | 0.90 | SLC6A1 (0.33) | DPP4SLC6A2SLC6A4SLC6A3CPN1 | |
| SCHEMBL31564804 | 0.87 | DPP4 (0.36) | DPP4NOS1NOS3NOS2HRH3 | |
| SCHEMBL14978004 | 0.87 | DPP4 (0.36) | DPP4NOS1NOS3NOS2HRH3 | |
| SCHEMBL27511091 | 0.84 | CPN1 (0.36) | SLC6A2SLC6A4SLC6A3CPN1CPB2 | |
| SCHEMBL27570839 | 0.84 | DPP4 (0.41) | DPP4 | |
| SCHEMBL15129485 | 0.82 | DPP4 (0.44) | DPP4 | |
| Hydrochloric Acid SCHEMBL6438617 | 0.82 | DPP4 (0.40) | DPP4 | |
| SCHEMBL2001522 | 0.82 | NOS1 (0.34) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160300-B | Coumarin compound, preparation method thereof and application of coumarin compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2024-05-31 | — | — | CN | claimed |
| CN-115160300-A | Coumarin compound, preparation method thereof and application of coumarin compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2022-10-11 | — | — | CN | claimed |
| CN-112047928-B | Isonicotinamide AChE-GSK3 double inhibitor and preparation method and application thereof | 中国药科大学 | 2022-09-23 | — | — | CN | claimed |
| CN-113511998-A | Synthesis method of 1-Boc-4-aminomethyl piperidine | 南通华祥医药科技有限公司 | 2021-10-19 | — | — | CN | claimed |
| CN-112047928-A | Isonicotinamide AChE-GSK3 double inhibitor and preparation method and application thereof | 中国药科大学 | 2020-12-08 | — | — | CN | claimed |
| EP-4680343-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119775346-A | E3 ubiquitin ligase ligand compound and application thereof | 天津医科大学 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025068371-A1 | INHIBITORS OF THE PROPROTEIN CONVERTASE FURIN, METHODS OF PRODUCTION THEREOF AND USE | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2025-04-03 | — | — | WO | disclosed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| CN-118754894-A | JQ1 derivative containing o-naphthoquinone structure, synthesis method thereof and application of JQ1 derivative in preparation of anti-triple-negative breast cancer drugs | 新乡医学院 | 2024-10-11 | — | — | CN | disclosed |
| US-5723444-A | ENZYME INHIBITORS AND ANTICOAGULANTS | ASTRA AB (SE) | 1998-03-03 | — | — | US | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
| EP-0774460-A1 | BENZOIC ACID COMPOUND AND USE THEREOF AS MEDICINE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| US-5602253-A | STARTING MATERIAL FOR SERINE PROTEASE INHIBITORS | AKTIEBOLAGET ASTRA (SE) | 1997-02-11 | — | — | US | disclosed |
| EP-0743320-A2 | Acyl guanidine and amidine prodrugs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| CN-1127509-A | Novel peptide derivatives | ASTRA AB (SE) | 1996-07-24 | — | — | CN | disclosed |
| EP-0701568-A1 | NEW PEPTIDE DERIVATIVES | Astra Aktiebolag (SE) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994029336-A1 | NEW PEPTIDE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | DPP4 1575/4885SLC6A2 4114/4885SLC6A4 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.